iPS-B-11
LUEi015-A
General
Cell Line |
|
hPSCreg name | LUEi015-A |
Cite as: | LUEi015-A (RRID:CVCL_A1WI) |
Alternative name(s) |
iPS-B-11
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease |
Last update | 4th November 2020 |
User feedback | |
Provider |
|
Generator | Institute of Neurogenetics (LUE) |
External Databases |
|
BioSamples | SAMEA7683939 |
Cellosaurus | CVCL_A1WI |
Wikidata | Q105509960 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA7683940 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | University of Luebeck |
Approval number | 05-030 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | University of Luebeck |
Approval number | 05-030 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type | |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
TRA 1-60 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
AFP |
Yes |
SOX17 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
MSX1 |
Yes |
MYH6 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
NCAM |
Yes |
PAX6 |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
No abnormalities detected
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.